RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Inc. (NASDAQ:SLXP) today announced that the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting® 2011), being held in San Francisco, CA, November 4-8, 2011, should be an important venue for ongoing discussion of complications associated with chronic liver disease, including overt hepatic encephalopathy, or OHE. Posters and oral presentations presented at the meeting should provide insight regarding OHE’s burden on patients, caregivers and the healthcare system; the earlier identification and diagnosis of OHE; the growing recognition of the importance of aggressive management of OHE; and the use of XIFAXAN® (rifaximin) 550 mg for the reduction in risk of overt HE recurrence in patients 18 years of age and older.
